| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Parkinson’s Disease Therapeutics Market Size 2024 |
USD 5,169.5 Million |
| Parkinson’s Disease Therapeutics Market, CAGR |
6.00% |
| Parkinson’s Disease Therapeutics Market Size 2032 |
USD 8,239.39 Million |
Market Overview
The Parkinson’s Disease Therapeutics Market is projected to grow from USD 5,169.5 million in 2023 to an estimated USD 8,239.39 million by 2032, reflecting a compound annual growth rate (CAGR) of 6.00% from 2024 to 2032. This expansion is driven by the increasing prevalence of Parkinson’s disease, coupled with advancements in therapeutic options aimed at managing the disease’s symptoms.
Key market drivers include the aging global population, increased government support for Parkinson’s research, and a robust pipeline of disease-modifying treatments. Technological advancements in drug delivery systems and the emergence of novel therapies, such as gene therapy and neurostimulation devices, are shaping the market landscape. Trends such as personalized medicine and targeted therapeutics continue to gain traction, supporting the market’s steady expansion.
Geographically, North America dominates the Parkinson’s Disease Therapeutics Market due to its advanced healthcare infrastructure, high prevalence of Parkinson’s, and substantial investment in research and development. Europe follows closely, supported by favorable reimbursement policies and increasing awareness initiatives. In the Asia-Pacific region, the market is growing rapidly, driven by an expanding elderly population and improving healthcare facilities. Key players in the market include AbbVie Inc., Biogen Inc., Pfizer Inc., and Medtronic Plc, all of which are focusing on strategic collaborations and product innovations to maintain competitive positions in this evolving market.
Access crucial information at unmatched prices!
Request your free sample report today & start making informed decisions powered by Credence Research!
Download Free Sample
Market Drivers
Rising Prevalence of Parkinson’s Disease
Parkinson’s disease is one of the fastest-growing neurological disorders worldwide, with millions affected, especially as the global population ages. The rising incidence of Parkinson’s disease, particularly among the elderly, is a significant driver of the market for therapeutics. With the world’s population of those aged 60 and over expected to double by 2050, the demand for treatments that can alleviate symptoms and improve quality of life is steadily increasing. This demographic trend is expected to contribute to the rising prevalence of Parkinson’s disease, thereby driving the growth of the therapeutics market. Additionally, improvements in diagnostic tools are helping clinicians detect Parkinson’s at earlier stages, further expanding the patient base eligible for treatment and driving demand for therapeutics. For instance, a 2022 study revealed that nearly 90,000 people are diagnosed with Parkinson’s disease every year in the United States, representing a 50% increase from previous estimates. Additionally, the World Health Organization reported that globally, the number of individuals with Parkinson’s disease reached over 8.5 million in 2019.
Advancements in Therapeutic Options
Over the past decade, considerable advancements have been made in the development of therapeutics for Parkinson’s disease. Traditional dopamine-based treatments, while effective, have been supplemented by new drugs and approaches, including levodopa-carbidopa intestinal gel, dopamine agonists, and monoamine oxidase B (MAO-B) inhibitors. Further advancements include extended-release formulations and the use of gene therapy, which offers the potential to slow disease progression or restore certain neurological functions. Neurostimulation devices, such as deep brain stimulators, have also shown promising results in treating symptoms of Parkinson’s. These innovations enhance treatment efficacy and allow patients to manage their symptoms more effectively, driving market growth by meeting a broader range of needs and improving patient outcomes. For instance, a review of Parkinson’s disease clinical trials from 2021 to 2022 found that 42.2% of interventions were novel therapies and 34% were repurposed agents. Additionally, a small trial published in June 2024 reported promising results for a potential immune-based treatment targeting alpha-synuclein, a protein involved in Parkinson’s disease.
Increasing Healthcare Expenditure and Government Support
Increased healthcare spending and government support for research and development play crucial roles in advancing the Parkinson’s Disease Therapeutics Market. Governments and healthcare organizations worldwide are recognizing the growing impact of neurological diseases like Parkinson’s on healthcare systems and societies. Consequently, many are investing significantly in research initiatives aimed at finding new treatments, improving patient care, and reducing healthcare costs associated with Parkinson’s disease. Additionally, the availability of funding grants and subsidies for the development of novel therapeutics and medical devices, coupled with support for clinical trials, fosters innovation within the sector. These investments not only accelerate the development and approval of new treatments but also make them more accessible, driving market expansion.
Growing Focus on Personalized Medicine and Targeted Therapeutics
The shift towards personalized medicine and targeted therapeutic approaches is a noteworthy trend in the Parkinson’s Disease Therapeutics Market. Personalized medicine involves tailoring treatment plans based on individual patient characteristics, such as genetic makeup, lifestyle, and disease stage. This approach has gained popularity because it offers the potential for more effective treatment outcomes, with fewer side effects. In the case of Parkinson’s disease, emerging treatments that target specific genetic or molecular mechanisms of the disease have the potential to slow or halt disease progression. Gene therapy, for instance, is being explored to address underlying genetic factors linked to Parkinson’s. The trend toward personalized and targeted treatments is driving innovation within the market, as pharmaceutical companies and researchers work to develop therapies that can deliver more precise and effective outcomes for patients.
Market Trends
Increased Focus on Disease-Modifying Treatments and Gene Therapy
Traditionally, Parkinson’s disease treatment has focused on symptomatic relief, primarily using dopamine replacement therapies to manage motor symptoms. However, a shift is underway towards developing disease-modifying treatments that go beyond symptom management and aim to alter the disease’s progression. Advances in genetics and molecular biology have made it possible to identify targets that may help slow down or even halt the neurodegenerative process. Gene therapy, in particular, has garnered substantial interest as a potential method for addressing the underlying causes of Parkinson’s disease. For example, therapies that deliver genes directly to the brain can help restore dopamine levels, and some approaches focus on repairing or replacing defective genes that contribute to the disease. As these innovative therapies progress through clinical trials, they hold the promise of providing longer-lasting and more effective outcomes for patients. For instance, a recent review of 145 active clinical trials of Parkinson’s disease drug therapeutics found that 39% were considered to be trials of disease-modifying candidates, with 42% of these in phase 1, 53% in phase 2, and 5% in phase 3. This trend towards disease modification represents a major shift in therapeutic strategies and is anticipated to reshape the future of the Parkinson’s Disease Therapeutics Market.
Growing Adoption of Advanced Drug Delivery Systems
The market is also seeing a notable rise in the development and adoption of advanced drug delivery systems aimed at improving treatment efficacy and patient adherence. While oral medications remain a mainstay in Parkinson’s treatment, challenges such as fluctuating drug levels and side effects have led to the exploration of alternative delivery methods. Transdermal patches, for example, provide a continuous and controlled release of medication, helping to maintain stable dopamine levels throughout the day. Another promising advancement is the use of intrajejunal or subcutaneous pumps, which deliver drugs directly to the site of action, bypassing the digestive system and enhancing absorption. Furthermore, researchers are exploring nano- and micro-particulate drug delivery systems to achieve more targeted and sustained drug release in the brain. These advanced delivery systems not only enhance the therapeutic benefits of existing medications but also improve patient convenience, resulting in higher treatment compliance and better overall management of Parkinson’s disease symptoms.
Market Restraints and Challenges
High Costs and Limited Accessibility of Advanced Therapies
One significant challenge in the Parkinson’s Disease Therapeutics Market is the high cost associated with advanced therapies and innovative treatment options. While groundbreaking treatments, such as gene therapy and neurostimulation devices, offer promising results, they are often accompanied by substantial price tags, making them inaccessible to a large portion of patients. Additionally, many health insurance plans offer limited coverage for these high-cost therapies, creating a financial burden on patients and their families. This high cost can be prohibitive in developing regions where healthcare infrastructure and funding are already limited, restricting the availability and adoption of new therapies. The affordability issue ultimately limits the market’s growth potential, as many patients who could benefit from these therapies remain unable to access them.
Lack of Curative Treatments and Complex Regulatory Pathways
Despite extensive research, Parkinson’s disease remains incurable, and most available treatments primarily focus on managing symptoms rather than addressing the underlying neurodegeneration. The lack of disease-modifying or curative treatments presents a considerable challenge to the market. Additionally, the complexity of developing such therapies is compounded by rigorous regulatory requirements, which extend the time and cost associated with bringing new products to market. Clinical trials for Parkinson’s disease often require lengthy observation periods and large patient populations to establish safety and efficacy, increasing the financial and logistical burden on pharmaceutical companies. Furthermore, the regulatory approval process for innovative treatments, such as gene therapies and cell-based therapies, remains uncertain and challenging, with strict guidelines that may delay market entry. These factors not only increase the cost and time required for new product development but also pose challenges for companies seeking to expand their portfolios with novel and potentially curative treatments.
Market Segmentation Analysis
By Drug Class
In the Parkinson’s Disease Therapeutics Market, Carbidopa-Levodopa stands out as the leading drug combination, widely used for its effectiveness in replenishing dopamine levels and managing motor symptoms, with continuous innovations like extended-release formulations enhancing patient compliance. Dopamine agonists, often used alone or with Carbidopa-Levodopa, are particularly favored in early-stage treatment, as they stimulate dopamine receptors and help delay the need for levodopa, especially in younger patients. MAO-B inhibitors, which slow dopamine breakdown in the brain, are commonly prescribed in initial stages or as adjunct therapy, and their market share is expanding due to their benefits for patients who experience side effects from other treatments. COMT inhibitors, though holding a smaller market share, complement Carbidopa-Levodopa by extending its effects through dopamine preservation. Anticholinergics, used primarily to reduce tremors and muscle rigidity in younger patients, serve a niche market due to side effect concerns, while the “Others” category, which includes options like Amantadine and neuroprotective agents, is gaining traction for treating non-motor symptoms and improving patient quality of life.
By Distribution Channel
Hospital pharmacies play a dominant role in distributing Parkinson’s disease therapeutics, as they provide medications to patients receiving inpatient and outpatient care, serving as the primary point of diagnosis and treatment initiation. Retail pharmacies also hold a significant share, offering convenient access for ongoing prescriptions and refills, making them essential for patients managing their condition at home. Meanwhile, the online pharmacy segment is rapidly growing due to the rise of e-commerce and the convenience it provides, particularly for patients with mobility challenges or limited access to physical pharmacies. The COVID-19 pandemic further accelerated this shift toward online purchasing, positioning online pharmacies as an increasingly important channel for Parkinson’s therapeutics distribution.
Segments
Based on Drug Class
- Carbidopalevodopa
- Dopamine Agonists
- MAOB Inhibitors
- COMT inhibitors
- Anticholinergics
- Others
Based on Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Based on Regional
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
Regional Analysis
North America (40%):
North America holds the largest share in the global Parkinson’s disease therapeutics market, accounting for approximately 40% of the total market share. This dominance is driven by the high prevalence of Parkinson’s disease, advanced healthcare infrastructure, and significant investment in research and development. The United States, in particular, leads within North America due to strong governmental support for neurological research, a well-established pharmaceutical industry, and comprehensive insurance coverage that supports patient access to innovative treatments. The presence of key market players in the region, coupled with an aging population, further fuels the demand for Parkinson’s therapeutics.
Europe (30%):
Europe holds around 30% of the global market share, making it the second-largest region in the Parkinson’s Disease Therapeutics Market. Countries such as Germany, the United Kingdom, and France are major contributors to this regional market due to their advanced healthcare systems and increased awareness about neurodegenerative diseases. European healthcare policies, including favorable reimbursement schemes and government-funded research programs, facilitate access to Parkinson’s treatments and foster innovation. The market in Europe is expected to grow steadily, supported by a rising geriatric population and continuous investments in research and development for novel therapeutics.
Key players
- Cerevel Therapeutics
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- GlaxoSmithKline plc. (GSK)
- AbbVie, Inc.
- Lundbeck A/S
- Amneal Pharmaceuticals LLC
- Supernus Pharmaceuticals, Inc.
Competitive Analysis
The Parkinson’s Disease Therapeutics Market is highly competitive, with several prominent players actively investing in research and development to bring innovative therapies to the market. AbbVie, Inc., for instance, has a strong portfolio with products like Duodopa, while Novartis AG and Teva Pharmaceutical Industries Ltd. are notable for their extensive generic and branded drug offerings for Parkinson’s management. Companies like Cerevel Therapeutics and H. Lundbeck A/S focus on neuroscience-driven research, driving forward new treatments targeting underlying disease mechanisms. Supernus Pharmaceuticals and Amneal Pharmaceuticals are also emerging players, concentrating on accessible, cost-effective treatment solutions. Key strategies employed by these companies include strategic alliances, mergers, and acquisitions to strengthen their product pipelines and expand their global reach. With a continued emphasis on developing disease-modifying therapies, these players are well-positioned to cater to the growing demand for Parkinson’s disease therapeutics worldwide.
Recent Developments
- In April 2024, Cerevel Therapeutics announced positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo.
- In April 2024, Teva announced a clinical collaboration agreement with Launch Therapeutics to accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248).
- In November 2023, Merck announced the acquisition of Caraway Therapeutics for up to $610 million, including preclinical candidates against Parkinson’s disease.
- In July 2021, GSK and Alector announced a global collaboration to develop monoclonal antibodies for neurodegenerative diseases, including Parkinson’s disease.
- In September 2024, AbbVie reported positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson’s disease.
- In August 2024, Lundbeck began clinical development of a new treatment for Parkinson’s disease with the enrollment of the first participant in a Phase I study with the compound Lu AF82422.
- In September 2024, Amneal launched CREXONT (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease.
- In August 2024, Supernus resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease.
Market Concentration and Characteristics
The Global Parkinson’s Disease Therapeutics Market is moderately concentrated, with a few key players holding substantial market shares, while numerous smaller and emerging companies compete for the remaining portions. The market is characterized by a strong focus on research and development, particularly in areas such as disease-modifying treatments, gene therapy, and advanced drug delivery systems. Established pharmaceutical giants like AbbVie, Novartis, and Teva have a competitive edge due to their broad therapeutic portfolios, robust distribution networks, and significant investment in clinical trials. Meanwhile, smaller biotech companies, such as Cerevel Therapeutics, are increasingly contributing to market diversity by pursuing innovative approaches to Parkinson’s treatment. The market also displays a high level of collaboration, with companies frequently engaging in partnerships, licensing agreements, and acquisitions to enhance their research capabilities and expand their geographic reach. This blend of established and emerging players contributes to a dynamic and competitive landscape focused on addressing the unmet needs of Parkinson’s disease patients.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Report Coverage
The research report offers an in-depth analysis based on Drug Class, Distribution Channel and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
- Pharmaceutical companies are expected to continue investing heavily in R&D, focusing on innovative therapies that target disease modification and provide long-term symptom relief.
- The market is likely to witness a shift towards personalized treatment approaches, driven by advances in genetic research and the need for targeted therapies that cater to individual patient profiles.
- Future growth is anticipated in advanced drug delivery systems, such as transdermal patches and intrajejunal pumps, which offer enhanced therapeutic efficacy and improved patient compliance.
- Gene therapy and regenerative treatments are poised to play a larger role in the market as companies develop solutions aimed at slowing or halting disease progression rather than merely managing symptoms.
- The Asia-Pacific region is expected to see rapid expansion due to its aging population, improving healthcare infrastructure, and increasing awareness of neurological diseases.
- Companies are likely to form more partnerships, licensing agreements, and joint ventures to pool resources, accelerate research, and expand their global presence in the competitive landscape.
- Future therapeutics will likely focus not only on motor symptoms but also on addressing non-motor symptoms, such as cognitive decline and mood disorders, which significantly impact patient quality of life.
- Regulatory bodies are expected to streamline approval pathways for groundbreaking therapies, such as gene therapy, which could accelerate market growth by making novel treatments more readily available.
- Progress in biomarker research is anticipated to lead to earlier and more accurate diagnosis of Parkinson’s disease, enabling timely therapeutic interventions and potentially slowing disease progression.
- The adoption of digital health technologies, such as wearable devices and telemedicine, is expected to rise, allowing for better disease monitoring, remote patient support, and personalized treatment adjustments.
